Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
Want to see SE:XSPRAY full AI Analyst Report?
XSPRAY Stock Chart & Stats
kr31.20
kr0.60(1.95%)
At close: 4:00 PM EST
kr31.20
kr0.60(1.95%)
Day’s Range― - ―
52-Week Rangekr22.46 - kr62.33
Previous CloseN/A
Volume2.99K
Average Volume (3M)297.70K
Market Cap
kr1.24B
Enterprise Valuekr1.17B
Total Cash (Recent Filing)kr153.75M
Total Debt (Recent Filing)kr170.11M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding45,916,573
10 Day Avg. Volume602,659
30 Day Avg. Volume297,696
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-6.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)kr157.50M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Equity BufferA sizable equity base (604.6M) relative to assets offers durable financial flexibility, letting the company fund R&D cycles and absorb losses without immediate insolvency. This buffer extends runway and enhances bargaining power with partners and creditors over the next several quarters.
Partnership/licensing Business ModelA licensing- and milestone-driven model reduces fixed commercial costs and scales revenue without building a full sales infrastructure. This structure aligns incentives with partners, lowers break-even capital needs, and can produce non-dilutive milestone/royalty streams once deals close, supporting long-term viability.
Proprietary Reformulation TechnologyA platform (HyNap) focused on reformulating oncology drugs targets lower-risk, value-enhancing improvements like bioavailability and reduced food effects. Such platform-led reformulations attract partners seeking differentiated, faster-to-market assets, enabling repeat licensing opportunities and durable IP-driven revenue potential.
Bears Say
No Commercial RevenueAn absence of commercial sales over multiple years means the business has not proven market monetization; reliance on future licensing milestones creates execution and timing risk. Without revenue, the company remains dependent on external funding or deals to sustain operations and advance programs.
Severe And Worsening Cash BurnDeepening negative operating cash flow signals ongoing high spending relative to inflows, implying repeated financing needs. Persistent cash burn constrains discretionary investment, risks dilutive capital raises, and forces prioritization or delay of programs, undermining the firm's ability to execute multiyear development plans.
Rising LeverageRapidly increasing debt raises fixed obligations and refinancing risk, reducing financial flexibility. Higher leverage limits ability to absorb further losses or fund trials internally, may increase cost of capital, and could complicate partnership negotiations if counterparties view credit risk as elevated.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr22.46 and its highest was kr62.33 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr1.24B.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is May 06, 2026 which is in 6 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Feb 12, 2026. The company reported -kr0.862 earnings per share for the quarter, missing the consensus estimate of kr1.706 by -kr2.568.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 45,916,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -kr0.862 in its last earnings report, missing expectations of kr1.706. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―